Evidence map›Paper›PMID 30243583›Full record

ArticleThe Lancet. Infectious diseases2018

Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016.

GBD 2016 Diarrhoeal Disease Collaborators

5 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in The Lancet. Infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 787 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
787citing papers in PubMed, 8 pooled it
83.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04335877 nacompletednot on this mapstarted 2021, after this paper: background citation

Effectiveness-Implementation Research to Assess the Effect of Prompting the Supply of Zinc/LO-ORS Co-packs Through the Private Sector Coupled With Behavior Change Intervention on the Treatment of Uncomplicated Childhood Diarrhoea in Kenya

TypeinterventionalSponsorNutrition InternationalRan2021 to 2022Enrolled1,245ConditionsDiarrhea, InfantileArmsPrivate sector component + modified BCC
NCT06122870 phase1completednot on this mapstarted 2023, after this paper: background citation

Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of CampETEC Hyperimmune Bovine Colostrum (HBC) for the Prevention of Campylobacter-Mediated Diarrheal Diseases

TypeinterventionalSponsorJohns Hopkins Bloomberg School of Public HealthRan2023 to 2025Enrolled27ConditionsHealthy VolunteerArmsCampETEC HBC product, ProMilk 85, C. jejuni CG8421 Challenge strain
NCT06839586 phase1 / phase2active not recruitingnot on this mapstarted 2025, after this paper: background citation

The Efficacy and Safety of CMTS4520 for Chronic Diarrhoea in Adults: A Randomized, Double-Blind, Placebo-Controlled Trial.

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2025 to 2030Enrolled100ConditionsDiarrhoeaArmsCMTS4520 (dietary fiber and probiotics), Placebo
NCT06839599 phase1 / phase2not yet recruitingnot on this mapstarted 2025, after this paper: background citation

The Efficacy and Safety of CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults: a Randomized, Double-Blind, Placebo-Controlled Trial.

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2025 to 2030Enrolled100ConditionsDiarrheaArmsCMTS4520 (dietary fiber probiotics), Placebo
NCT07767370 early_phase1recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomised, Controlled, Double-blind Exploratory Study of ND-12 Combined With H-6 in the Treatment of Adult Chronic Inflammatory Diarrhea

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2026 to 2028Enrolled36ConditionsDiarrhea Chronic, UC - Ulcerative ColitisArmsmesalazine, ND-12, ND-12/H-6
3 · Its place in the literature

Who cites it

787 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,489 citations in OpenAlex.

  1. Burden ofBMJ global health · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Human vaccines & immunotherapeutics · 2026
    Review
  18. Article
  19. Article
  20. Draft genome sequences of 22Microbiology resource announcements · 2026
    Article

727 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

GBD 2016 Diarrhoeal Disease Collaborators

Funding

Quantitative molecular diagnostics for diarrhea etiology and vaccine efficacyK23AI114888 · NIAID · UNIVERSITY OF VIRGINIA · PI PLATTS-MILLS, JAMES ALEXANDER · 2015 to 2019
$932k
NIAID NIH HHS K23 AI114888Wellcome Trust 109949/Z/15/Z
6 · The paper itself

Abstract

backgroundThe Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2016 provides an up-to-date analysis of the burden of diarrhoea in 195 countries. This study assesses cases, deaths, and aetiologies in 1990-2016 and assesses how the burden of diarrhoea has changed in people of all ages.

methodsWe modelled diarrhoea mortality with a Bayesian hierarchical modelling platform that evaluates a wide range of covariates and model types on the basis of vital registration and verbal autopsy data. We modelled diarrhoea incidence with a compartmental meta-regression tool that enforces an association between incidence and prevalence, and relies on scientific literature, population representative surveys, and health-care data. Diarrhoea deaths and episodes were attributed to 13 pathogens by use of a counterfactual population attributable fraction approach. Diarrhoea risk factors are also based on counterfactual estimates of risk exposure and the association between the risk and diarrhoea. Each modelled estimate accounted for uncertainty.

findingsIn 2016, diarrhoea was the eighth leading cause of death among all ages (1 655 944 deaths, 95% uncertainty interval [UI] 1 244 073-2 366 552) and the fifth leading cause of death among children younger than 5 years (446 000 deaths, 390 894-504 613). Rotavirus was the leading aetiology for diarrhoea mortality among children younger than 5 years (128 515 deaths, 105 138-155 133) and among all ages (228 047 deaths, 183 526-292 737). Childhood wasting (low weight-for-height score), unsafe water, and unsafe sanitation were the leading risk factors for diarrhoea, responsible for 80·4% (95% UI 68·2-85·0), 72·1% (34·0-91·4), and 56·4% (49·3-62·7) of diarrhoea deaths in children younger than 5 years, respectively. Prevention of wasting in 1762 children (95% UI 1521-2170) could avert one death from diarrhoea.

interpretationSubstantial progress has been made globally in reducing the burden of diarrhoeal diseases, driven by decreases in several primary risk factors. However, this reduction has not been equal across locations, and burden among adults older than 70 years requires attention.

fundingBill & Melinda Gates Foundation.

Indexed as

Global HealthAdolescentAdultAgedAged, 80 and overBacterial InfectionsBiostatisticsChildChild, PreschoolCost of IllnessDiarrheaEpidemiologic MethodsFemaleHumansIncidenceInfant

Identifiers

PMID30243583
PMCPMC6202444
OpenAlexW2891808294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.